Drugs Made In America Acquisition Corp- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Drugs Made In America Acquisition Corp 公司

Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues.

Drugs Made In America Acquisition Corp簡介



公司代碼DMAA

公司名稱Drugs Made In America Acquisition Corp

上市日期Jan 28, 2025

CEOStockwell (Lynn)

員工數量- -

證券類型Ordinary Share

年結日Jan 28

公司地址1 East Broward Boulevard

城市FT LAUDERDALE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編33301

電話19548703099

網址

公司代碼DMAA

上市日期Jan 28, 2025

CEOStockwell (Lynn)

Drugs Made In America Acquisition Corp公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Catherine Do

Independent Director Nominee

100.00K

--

Ms. Lynn Stockwell

Executive Chairman of the Board, Chief Executive Officer

--

Dr. G. Sridhar Prasad

Independent Director Nominee

--

Mr. Myron W. Shulgan

Independent Director Nominee

--

Mr. Saleem Elmasri, CPA

Chief Financial Officer, Principal Financial and Accounting Officer

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Catherine Do

Independent Director Nominee

100.00K

--

Ms. Lynn Stockwell

Executive Chairman of the Board, Chief Executive Officer

--

Dr. G. Sridhar Prasad

Independent Director Nominee

--

Mr. Myron W. Shulgan

Independent Director Nominee

--

Mr. Saleem Elmasri, CPA

Chief Financial Officer, Principal Financial and Accounting Officer

--

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 5月7日週四

持股股東

股東類型

持股股東

佔比

Drugs Made In America Acquisition LLC

12.42%

Karpus Investment Management

7.53%

First Trust Capital Management L.P.

6.65%

Mizuho Securities USA, LLC.

5.93%

Glazer Capital, LLC

5.39%

其他

62.08%

持股股東

佔比

Drugs Made In America Acquisition LLC

12.42%

Karpus Investment Management

7.53%

First Trust Capital Management L.P.

6.65%

Mizuho Securities USA, LLC.

5.93%

Glazer Capital, LLC

5.39%

其他

62.08%

股東類型

持股股東

佔比

Hedge Fund

30.86%

Investment Advisor/Hedge Fund

23.94%

Corporation

12.42%

Investment Advisor

8.51%

Research Firm

5.68%

Individual Investor

0.89%

其他

17.70%

機構持股



更新時間: 4月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2026Q1

54

23.26M

68.99%

-2.07M

2025Q4

47

22.21M

67.76%

-8.45K

2025Q3

47

22.22M

67.76%

+1.02M

2025Q2

38

21.21M

54.90%

+2.81M

2025Q1

25

18.33M

0.00%

+18.33M

2024Q4

5

4.59M

15.73%

+4.59M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Drugs Made In America Acquisition LLC

8.57M

25.57%

+4.38M

+104.63%

Feb 25, 2025

Karpus Investment Management

2.54M

7.57%

-9.03K

-0.35%

Dec 31, 2025

First Trust Capital Management L.P.

2.24M

6.69%

--

Dec 31, 2025

Mizuho Securities USA, LLC.

1.43M

4.28%

+333.04K

+30.26%

Dec 31, 2025

Glazer Capital, LLC

1.82M

5.42%

-5.86K

-0.32%

Dec 31, 2025

Westchester Capital Management, LLC

1.67M

4.98%

--

Dec 31, 2025

Polar Asset Management Partners Inc.

1.60M

4.77%

-300.00K

-15.79%

Dec 31, 2025

Wolverine Asset Management, LLC

1.31M

3.9%

+58.34K

+4.67%

Dec 31, 2025

Hudson Bay Capital Management LP

1.55M

4.62%

--

Dec 31, 2025

Aristeia Capital, L.L.C.

881.72K

2.63%

--

Dec 31, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

CrossingBridge Pre-Merger SPAC ETF

0%

CrossingBridge Pre-Merger SPAC ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據